Irritable Bowel Syndrome Clinical Trial
— IBS-PlusOfficial title:
An Assessment of the Efficacy of Microencapsulated Sodium Butyrate and a Probiotic Mixture in Patients With Irritable Bowel Syndrome - a Randomized Double-blind Placebo-controlled Study
Verified date | February 2024 |
Source | Nordic Biotic Sp. z o.o. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
According to current IBS management guidelines, probiotic administration reduces IBS-associated symptoms and improves the quality of life. The purpose of this study is to assess the effects of the combined formulation comprising microencapsulated sodium butyrate and a probiotic mixture of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum, and B. lactis) on the incidence and severity of clinical symptoms in patients diagnosed with irritable bowel syndrome (IBS) based on the Rome IV criteria. Microencapsulated sodium butyrate is a short-chain fatty acid (SCFA) with biological effects on the gastrointestinal mucosa; it constitutes a key source of energy for enterocytes. Butyrate was shown to have a trophic effect on the colon epithelium and to help restore the disrupted structural and functional integrity of the gastrointestinal tract. These unique properties of sodium butyrate result in its beneficial effects on the abdominal symptoms (such as diarrhea, constipation, abdominal pain) in patients with IBS. This study will assess the effects of the mixture of sodium butyrate and multi-strain probiotic on the rate and severity of clinical symptoms in IBS patients, by taking into account their nutritional status and body composition.
Status | Completed |
Enrollment | 120 |
Est. completion date | January 31, 2024 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Males and females aged from 18 to 70 years, inclusive; 2. Good physical and mental condition assessed based on the patient's history and physical examination; 3. Laboratory test results (complete blood count, blood chemistry panel) within normal limits or considered not to be clinically significant by the Investigator; negative SARS-CoV-2 antibody test; 4. A voluntarily provided written informed consent; 5. Diagnosis of IBS based on the Rome IV criteria, e.g. recurrent abdominal pain at least one day a week for the last three months, associated with two or more of the following symptoms (these should be present for the last three months, with the onset of symptoms six months before diagnosis): - related to defecation - associated with a change in stool frequency and/or - associated with a change in stool form (appearance) Patients with any of the following forms of IBS will be included: - IBS-D - more than 25% of BSF type 6 and 7 stools, and less than 25% of type 1 and 2 stools. - IBS-C - more than 25% of BSF type 1 and 2 stools, with less than 25% of type 6 and 7 stools. - IBS-M - more than 25% of BSF type 6 and 7 stools and also more than 25% of type 1 and 2 stools. - at least moderate symptom severity defined as an IBS-SSS score of >175 (5 items, maximum score 500). 6. The following medications are allowed during this study, provided they have been used at a stable dose and for at least 1 month prior to the study: 1. contraceptive pills or intramuscular contraceptives, 2. hormone replacement therapy (estrogen/progesterone), 3. L-thyroxine, 4. antidepressants at low doses (up to 25 mg of amitriptyline, nortriptyline, or selective serotonin reuptake inhibitor per day) 5. antihypertensives at low doses (diuretics, angiotensin converting enzyme inhibitors angiotensin receptor antagonists). Exclusion Criteria: 1. Unclassified IBS; 2. Cardiovascular disorders: uncontrolled hypertension (blood pressure >170/100 mmHg), cerebrovascular disease; 3. Respiratory disorders (asthma, chronic obstructive pulmonary disease [COPD]). 4. Hepatic impairment (including status post cholecystectomy), renal impairment, and unexplained blood biochemistry abnormalities: serum creatinine levels over twice the upper limit of normal, AST or ALT levels over twice the upper limit of normal. 5. Gastrointestinal conditions other than IBS, including clinical or endoscopic diagnosis of gastroenteritis. 6. Endocrine disorders, including diabetes mellitus (fasting blood glucose >11 mmol/L) and elevated TSH levels. 7. Severe neurological conditions, with psychosis; 8. Malignancy; 9. Pregnancy or breastfeeding; 10. Hypersensitivity to soy; 11. Lactose intolerance; 12. The use of gastrointestinal motility stimulants or dietary fiber supplements during the 2 weeks preceding the clinical study; 13. The use of antithrombotic drugs; 14. A surgical procedure scheduled during the course of the clinical study; 15. Current probiotic use and refusal to undergo a 3-month washout period; 16. Antibiotic therapy during the 3 months preceding the study; 17. Antibiotic use during the study; 18. Being included in another clinical study during the previous 3 months; 19. History of alcohol or substance; 20. Inability to strictly adhere to the Investigators' instructions regarding study procedures and protocol requirements.abuse. |
Country | Name | City | State |
---|---|---|---|
Poland | Medical University of Lodz | Lódz |
Lead Sponsor | Collaborator |
---|---|
Nordic Biotic Sp. z o.o. | Medical University of Lodz |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in interleukin 6 (IL-6) and macrophage inflammatory protein 1ß (MIP-1ß) levels | IL-6 and MIP-1ß levels will be measured in the sera of patients using commercially available immunoenzymatic tests. | From baseline at 4 and 12 weeks of intervention | |
Primary | Changes in severity of IBS symptoms using IBS Severity Scoring System (IBS-SSS) | IBS-SSS is a 5-question survey that asks: 1. the severity of abdominal pain, 2. frequency of abdominal pain, 3. severity of abdominal distention, 4.dissatisfaction with bowel habit, and 5. interference with quality of life over the past 10 days. Subjects respond to each question on a 100-point visual analogue scale. Each of the five question generates a maximum score of 100 point, and total scores can range from 0-500 with higher scores indicating severe symptoms. | Severity of symptoms from baseline at 4, 8 and 12 weeks of intervention | |
Primary | Improvement or worsening of IBS global symptoms using Global Improvement Scale (IBS-GIS) | IBS-Global Improvement Scale asseses IBS symptoms using a patient-defined 7 point Linkert scale ranging from symptoms substantially worse to substantially improved.
Patients answer the question "Have you felt any change in the severity of your symptoms over the past 7 days compared to how you felt before the medicine was given? The answers are recorded based on the 7-point scale: = I feel that the symptoms have worsened significantly = I feel that the symptoms have moderately worsened = I feel that the symptoms have slightly worsened = I feel no change = I feel a slight improvement = I feel moderate improvement = I feel significant improvement IBS-GIS score indicates: improvement if is >4 or worsening if is<4, no change if is 4. |
Improvement/worsening assessed after 4, 8 and 12 weeks of intervention | |
Primary | Changes in an adequate relief | IBS-Adequate Relief (IBS-AR) is a dichotomous single item that asks participants "Over the past week (7 days) have you had adequate relief of your IBS symptoms? The answer is YES or NO. | Adequate Relief after 4, 8 and 12 weeks of interventions | |
Primary | Changes in Quality of Life | The IBS-Quality of Life (IBS-QOL) is a 34-item measure assessing the degree to which IBS interferes with patient quality of life. Each item is rated on a 5-point Likert scale, thus yielding a total score that has a theoretical range of 34 to 170, with higher scores indicating worse QOL. | Quality of Life from baseline at 4, 8 and 12 weeks of intervention | |
Secondary | Changes in number and type of stools | Number of stools per day and type of stools assessed before intervention and then 3 times a week. Type of stools assessed using the Bristol Stool Formation Scale. Bristol Scale is designed to classify faeces into seven groups: type 1-2 indicate constipation, type 3-4 are "normal" stools; type 5-7 indicate diarrhea. | From baseline for 12 weeks of intervention in 1 week intervals | |
Secondary | Changes in severity of pain | The severity of pain assessed before intervention and then 3 times a week using a patient-defined 5 point Linkert scale: point 0 - no pain, and 1-4 the severity of pain with higher scores indicating worse pain. | From baseline for 12 weeks of intervention in 1 week intervals | |
Secondary | Changes in flatulence/abdominal distension | The severity of flatulence/abdominal distension assessed before intervention and then 3 times a week using a patient-defined 5 point Linkert scale: point 0 - no flatulence/abdominal distension, and 1-4 the severity of flatulence/abdominal distension with higher scores indicating worse flatulence/abdominal distension. | From baseline for 12 weeks of intervention in 1 week intervals | |
Secondary | Changes in Body Mass Index (BMI) | The effect of intervention on the patient's weight | From baseline at 4 and 12 weeks of intervention | |
Secondary | Body composition analysis | Body composition will be measured via bioelectrical impedance analysis with the use of a Bodystat machine. | From baseline at 4 and 12 weeks of intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |